ERBB2 and breast carcinoma: These biomarkers are critical in the initial diagnosis of breast cancer and for determining whether endocrine therapy or HER2-targeted therapy is necessary; however, studies have shown that subtypes derived from these 3 biomarkers are sub-optimal surrogates for the PAM50-based breast cancer intrinsic subtypes [5, 7, 34].